Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People whose cancer has spread to other parts of the body or cannot be surgically removed
• People diagnosed with a specific type of bladder cancer classed as a "variant histology" (such as nested, micropapillary, plasmacytoid, sarcomatoid, or similar subtypes) or a non-urothelial bladder cancer of epithelial origin (such as squamous cell carcinoma or adenocarcinoma), including cancers arising from related nearby structures such as the ureter, urethra, or renal pelvis — mixed tumour types may also be eligible if more than half of the tumour is one of these subtypes (confirm with trial site)
• People who have received any number of previous cancer treatments, or none at all
• People who are well enough to carry out normal daily activities, or who have only minor limitations (assessed using a standard medical scale called ECOG, score 0 or 1)
• People who have measurable tumour(s) visible on a CT or MRI scan meeting specific size requirements
• People with adequate organ and bone marrow function, based on tests done within 28 days before starting treatment
• People who have a tumour tissue sample available, or who are willing to have a biopsy taken before treatment starts
• People with a life expectancy of more than 12 weeks, as judged by the treating doctor
• Women of childbearing potential who have a negative pregnancy test before starting treatment
• People (and their partners) who agree to use reliable contraception during the trial and for 6 months after the last dose, and who agree not to donate eggs or sperm during this period
• People who have finished all previous cancer treatments (including surgery, radiotherapy, chemotherapy, immunotherapy, or experimental treatments) at least 4 weeks before starting the trial
• People who are willing and able to follow the trial schedule, attend visits, take medications as directed, and complete required tests
• People who have been fully informed about the trial and have given their written consent to participate

Who may not be able to join:

• People whose bladder cancer is of a neuroendocrine type (such as small cell or large cell carcinoma) or a non-epithelial type (such as sarcoma, melanoma, paraganglioma, or primary lymphoma of the bladder)
• People who have had chemotherapy or radiotherapy within the 4 weeks before joining, or who are still experiencing significant side effects (grade 2 or higher, except hair loss) from previous treatment
• People currently taking part in another clinical trial or using another experimental treatment within 21 days before the first dose
• People with a known allergy to medications that are chemically or biologically similar to the drugs used in this trial
• People with ongoing nerve damage affecting sensation or movement, rated at a moderate or severe level (grade 2 or higher)
• People who have previously been treated with the specific drugs used in this trial (EV or a PD-1/PD-L1 checkpoint inhibitor), including as maintenance therapy
• People with poorly controlled diabetes (confirm specific blood sugar thresholds with trial site)
• People with active cancer that has spread to the brain or spinal cord
• People who have had another active cancer in the past 24 months, with some exceptions such as certain skin cancers or localised prostate cancer (confirm with trial site)
• People currently receiving systemic antibiotic or antifungal treatment for an active infection, or taking high-dose steroid medications
• Women of childbearing potential with a positive pregnancy test at the start of the trial
• Women who are currently breastfeeding
• People with an autoimmune disease that has required systemic medical treatment in the past 2 years, or with active hepatitis B, active hepatitis C, or active tuberculosis
• People with a history of active eye conditions involving the cornea, such as keratitis or corneal ulcers
• People who have received an organ or tissue transplant from another person
• People with serious heart conditions, including severe heart failure, unstable chest pain, or significant heart rhythm problems occurring within the past 6 months
• People with other serious uncontrolled medical or psychiatric conditions that could affect their ability to participate safely in the trial

Important: Always verify eligibility with the trial site directly before applying.